Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

Global cancer statistics in the year 2000

Parkin, D. M. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00486-7 · Cited by 2,445 · see citing works

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377 · see citing works

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605 · see citing works

A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization

Sukhatme, V. P., Cao, X., Chang, L. C., Tsai‐Morris, C., Stamenkovich, D., Ferreira, P. C. P., Cohén, D., Edwards, S. A., Shows, T. B., Curran, T., et al. (1988) · Cell · doi:10.1016/0092-8674(88)90485-0 · Cited by 1,249 · see citing works

Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,220 · see citing works

The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway

Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 922 · see citing works

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Engelman, J. A., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 706 · see citing works

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations

Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., Ogino, H., Kakiuchi, S., Hanibuchi, M., Nishioka, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1643 · Cited by 643 · see citing works

KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

Massarelli, E., Varella‐Garcia, M., Tang, X., Xavier, A. C., Ozburn, N. C., Liu, D. D., Bekele, B. N., Herbst, R. S., & Wistuba, I. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3043 · Cited by 594 · see citing works

KRAS Mutations in Non-Small Cell Lung Cancer

Riely, G. J., Marks, J., & Pao, W. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200809-107lc · Cited by 550 · see citing works

<i>PTEN</i> Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J., Fischer, F., Frommolt, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4055 · Cited by 504 · see citing works

Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp

Nagai, Y., Miyazawa, H., Huqun, Tanaka, T., Udagawa, K., Kato, M., Fukuyama, S., Yokote, A., Kobayashi, K., Kanazawa, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0331 · Cited by 503 · see citing works

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

Soria, J., Lee, H., Lee, J. I., Luo, W., Issa, J. J., Kemp, B. L., Liu, D. D., Kurie, J. M., Mao, L., & Khuri, F. R. (2002) · PubMed · Cited by 406 · see citing works

The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling

Virolle, T., Adamson, E. D., Baron, V. T., Birle, D. C., Mercola, D., Mustelin, T., & de Belle, I. (2001) · Nature Cell Biology · doi:10.1038/ncb1201-1124 · Cited by 399 · see citing works

One Hundred Years of Lung Cancer

Spiro, S. G., & Silvestri, G. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-531oe · Cited by 379 · see citing works

Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs

Ono, M., & Kuwano, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0646 · Cited by 364 · see citing works

Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation

Ono, M., Hirata, A., Kometani, T., Miyagawa, M., Ueda, S.-I., Kinoshita, H., Fujii, T., & Kuwano, M. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.465.3.4 · Cited by 305 · see citing works

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

She, Q., Solit, D. B., Basso, A., & Moasser, M. M. (2003) · PubMed · Cited by 287 · see citing works

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

Anido, J., Matar, P., Albanell, J., Guzmán, M., Rojo, F., Arribas, J., Averbuch, S. D., & Baselga, J. M. (2003) · PubMed · Cited by 247 · see citing works

Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer

Yu, J. Q., Kane, S. E., Wu, J., Benedettini, E., Li, D., Reeves, C., Innocenti, G., Wetzel, R., Crosby, K., Becker, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2739 · Cited by 235 · see citing works

Egr-1 Activates Basic Fibroblast Growth Factor Transcription

Biesiada, E., Razandi, M., & Levin, E. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18576 · Cited by 200 · see citing works

Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status

Onitsuka, T., Uramoto, H., Nose, N., Takenoyama, M., Hanagiri, T., Sugio, K., & Yasumoto, K. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.022 · Cited by 142 · see citing works

Egr1 Transcription Factor: Multiple Roles in Prostate Tumor Cell Growth and Survival

Adamson, E. D., & Mercola, D. (2002) · Tumor Biology · doi:10.1159/000059711 · Cited by 137 · see citing works

Transcriptional regulation of the Icam-1 gene in antigen receptor- and phorbol ester-stimulated B lymphocytes: role for transcription factor EGR1.

Maltzman, J. S., Carmen, J. A., & Monroe, J. G. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.4.1747 · Cited by 133 · see citing works

Why is PTEN an important tumor suppressor?

Li, L., & Ross, A. H. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21593 · Cited by 118 · see citing works

Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis

Kawahara, A., Yamamoto, C., Nakashima, K., Azuma, K., Hattori, S., Kashihara, M., Aizawa, H., Basaki, Y., Kuwano, M., Kage, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3239 · Cited by 114 · see citing works

HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells

Hirata, A., Hosoi, F., Miyagawa, M., Ueda, S.-I., Naito, S., Fujii, T., Kuwano, M., & Ono, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2748 · Cited by 109 · see citing works

EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

Cappuzzo, F., Ligorio, C., Toschi, L., Rossi, E., Trisolini, R., Paioli, D., Magrini, E., Finocchiaro, G., Bartolini, S., Cancellieri, A., et al. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000268676.79872.9b · Cited by 89 · see citing works

Transforming Growth Factor-α Enhances Cyclin D1 Transcription through the Binding of Early Growth Response Protein to a cis-Regulatory Element in the Cyclin D1 Promoter

Yan, Y., Nakagawa, H., Lee, M.-H., & Rustgi, A. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.52.33181 · Cited by 88 · see citing works

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients

Endoh, H., Yatabe, Y., Kosaka, T., Kuwano, H., & Mitsudomi, T. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30374-9 · Cited by 82 · see citing works

The Reciprocal Role of Egr-1 and Sp Family Proteins in Regulation of the PTP1B Promoter in Response to the p210 Bcr-Abl Oncoprotein-tyrosine Kinase

Fukada, T., & Tonks, N. K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101354200 · Cited by 62 · see citing works

APE1/Ref-1 regulates PTEN expression mediated by Egr-1

Fantini, D., Fantini, D., Vascotto, C., Deganuto, M., Bivi, N., Gustincich, S., Marcon, G., Quadrifoglio, F., Damante, G., Bhakat, K. K., et al. (2008) · Free Radical Research · doi:10.1080/10715760701765616 · Cited by 60 · see citing works

Basic fibroblast growth factor transcriptional autoregulation requires EGR-1

Wang, D. M., Mayo, M. W., & Baldwin, A. S. (1997) · Oncogene · doi:10.1038/sj.onc.1201069 · Cited by 59 · see citing works

PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors

Kudoh, S., Yoshimura, A., Kataoka, K., et al. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.5.1157 · Cited by 53 · see citing works

PTEN expression elicited by EGR‐1 transcription factor in calyculin A‐induced apoptotic cells

Okamura, H., Yoshida, K., Morimoto, H., et al. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20283 · Cited by 38 · see citing works

Detection of Oncogenic Mutations in the EGFR Gene in Lung Adenocarcinoma with Differential Sensitivity to EGFR Tyrosine Kinase InhibitorsPreprint

Thomas, R. K., Greulich, H. E., Yuza, Y., LEE, J. C., Tengs, T., Feng, W. W., CHEN, T.-H., Nickerson, E., SIMONS, J., EGHOLM, M., et al. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.056 · Cited by 38 · see citing works

Molecular determinants of response to RTK‐targeting agents in nonsmall cell lung cancer

Reinmuth, N., Meister, M. A., Muley, T., Steins, M. B., Kreuter, M., Herth, F. J. F., Hoffmann, H., Dienemann, H., & Thomas, M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21750 · Cited by 18 · see citing works

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201 · see citing works

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

Kim, Y., Lee, B., Shim, J. H., Lee, S.-H., Park, W.-Y., Choi, Y.-L., Sun, J.-M., Ahn, J. S., Ahn, M.-J., & Park, K. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.150 · Cited by 174 · see citing works

Targeting EGFR ^L858R/T790M and EGFR ^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal chemistry

Lu, X., Yu, L., Zhang, Z., Ren, X., Smaill, J. B., & Ding, K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21488 · Cited by 173 · see citing works

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas

Cortot, A. B., & Jänne, P. A. (2014) · European Respiratory Review · doi:10.1183/09059180.00004614 · Cited by 158 · see citing works

A genetic interaction analysis identifies cancer drivers that modify EGFR dependency

Liao, S., Davoli, T., Leng, Y., Li, M. Z., Xu, Q., & Elledge, S. J. (2017) · Genes &amp; Development · doi:10.1101/gad.291948.116 · Cited by 67 · see citing works

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations

Cardona, A. F., CLICaP, O. B. O. T., Rojas, L., Wills, B., Arrieta, O., Carranza, H., Vargas, C., Otero, J., Corrales-Rodriguez, L., Martín, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12112 · Cited by 29 · see citing works

An illustration of survival analysis: A study of intensive care unit patients

Estarelles, R., & Pascori, J. (1991) · Controlled Clinical Trials · doi:10.1016/0197-2456(91)90217-a

Role of Epidermal Growth Factor Receptor Mutational Testing in Personalising the Treatment of Non-small-cell Lung Cancer

Ginsburg, P. J. (2010) · European Oncology & Haematology · doi:10.17925/eoh.2010.06.02.22

Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging

Marko‐Varga, G., Fehniger, T. E., Rezeli, M., Döme, B., Laurell, T., & Végvári, Á. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.03.019 · Cited by 112 · see citing works

Role of Epidermal Growth Factor Receptor Mutational Testing in Personalizing the Treatment of Non-small-cell Lung Cancer

Ginsburg, P. J. (2010) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2010.06.0.28

Harnessing plasma genotyping for precision therapy against lung cancer

Yan, X., & Fang, B. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.10.95 · Cited by 1 · see citing works